CVRx, Inc.(CVRX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,569 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
CVRX Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for CVRx, Inc. (CVRX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CVRX at 28.1/100 on a 32-signal composite quality model, placing it at rank #2,569 of 2,962 stocks — the bottom half of the AI-ranked universe. CVRX scores in the top quartile across revenue growth (79.7). Areas of concern include balance sheet strength (3.7) and free cash flow (7.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 9.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), CVRx, Inc. reports quarterly revenue of $15.7M, net income of $-14.0M, an operating margin of -82.9%. Top institutional holders of CVRX by reported 13-F value include JOHNSON & JOHNSON, NEA Management Company, BlackRock, based on the most recent SEC filings. CVRX trades on the Nasdaq exchange and files with the SEC under CIK 1235912. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CVRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CVRx, Inc. directly from SEC EDGAR. CVRx, Inc.'s 13F Pro composite quality score has ranged between 21 and 30 since 2022, currently 28.1 — an improving long-term trajectory across 64 quarterly and live scoring snapshots.
Revenue
Q2 2026
$15.7M
Net Income
Q2 2026
$-14.0M
Free Cash Flow
Q2 2026
$-8.9M
Operating Margin
Q2 2026
-82.9%
ROIC
Q2 2026
-66.3%
D/E Ratio
Q2 2026
2.94
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+10.4% YoYNet Income
+11.1% YoYOperating Income
+13.8% YoYEPS (Diluted)
+23.0% YoYTotal Assets
-21.5% YoYTotal Debt
+0.5% YoYOp. Cash Flow
-2.6% YoYFree Cash Flow
-0.6% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $56.7M +10.4% | $51.3M +30.5% | $39.3M +74.9% | $22.5M +72.4% | $13.0M +115.4% | $6.1M |
| Net Income | $-53.3M +11.1% | $-60.0M -45.5% | $-41.2M +0.6% | $-41.4M +3.8% | $-43.1M -205.3% | $-14.1M |
| Operating Income | $-51.3M +13.8% | $-59.5M -38.0% | $-43.1M -1.4% | $-42.5M -63.8% | $-26.0M -125.5% | $-11.5M |
| EPS (Diluted) | $-2.04 +23.0% | $-2.65 -33.2% | $-1.99 +1.5% | $-2.02 +51.4% | $-4.16 | — |
| Total Assets | $104.8M -21.5% | $133.4M +15.8% | $115.2M -7.8% | $124.9M -18.1% | $152.5M +135.5% | $64.8M |
| Total Debt | $49.5M +0.5% | $49.3M +68.6% | $29.2M +333.1% | $6.7M | $0.00 -100.0% | $19.3M |
| Operating Cash Flow | $-40.2M -2.6% | $-39.1M -0.3% | $-39.0M +8.6% | $-42.7M -53.9% | $-27.7M -72.3% | $-16.1M |
| Free Cash Flow | $-40.8M -0.6% | $-40.5M -2.3% | $-39.6M +8.6% | $-43.4M -50.0% | $-28.9M -76.2% | $-16.4M |
Get alerted when CVRX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for CVRx, Inc. including:
Top Institutional Holders of CVRX
JOHNSON & JOHNSON
$20.7M4,024,861 shNEA Management Company, LLC
$10.0M1,954,440 shBlackRock, Inc.
$6.4M1,245,459 shROYAL BANK OF CANADA
$6.3M1,233,212 shGSK plc
$5.2M1,007,583 shVANGUARD CAPITAL MANAGEMENT LLC
$4.7M910,576 shSILVERCREST ASSET MANAGEMENT GROUP LLC
$4.5M878,109 shGEODE CAPITAL MANAGEMENT, LLC
$2.3M440,786 shPFM Health Sciences, LP
$1.9M369,572 shSTATE STREET CORP
$1.9M366,352 sh
| Fund | Value | Shares |
|---|---|---|
| JOHNSON & JOHNSON | $20.7M | 4,024,861 |
| NEA Management Company, LLC | $10.0M | 1,954,440 |
| BlackRock, Inc. | $6.4M | 1,245,459 |
| ROYAL BANK OF CANADA | $6.3M | 1,233,212 |
| GSK plc | $5.2M | 1,007,583 |
| VANGUARD CAPITAL MANAGEMENT LLC | $4.7M | 910,576 |
| SILVERCREST ASSET MANAGEMENT GROUP LLC | $4.5M | 878,109 |
| GEODE CAPITAL MANAGEMENT, LLC | $2.3M | 440,786 |
| PFM Health Sciences, LP | $1.9M | 369,572 |
| STATE STREET CORP | $1.9M | 366,352 |
Companies Similar to CVRX
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
CHAMPIONS ONCOLOGY, INC.
BICYCLE THERAPEUTICS PLC
Xencor Inc
CYTOKINETICS INC
Tango Therapeutics, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put CVRX on your watchlist
Track score changes the day CVRx, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is CVRX a good stock to buy?
13F Pro's AI-powered analysis of CVRx, Inc. (CVRX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CVRX are available on the CVRX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. CVRX is classified as a small company.
Which hedge funds own CVRX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CVRX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of CVRx, Inc.'s investment landscape.